Dry Eye Disease for Paraoptometrics: Types, Assessment & Management

Q: What are the three layers of the tear film and what does each do?

The tear film has three distinct layers, each produced by different cells: (1) Lipid layer (outermost) — produced by meibomian glands in the tarsal plates of the eyelids. This oily layer retards evaporation of the aqueous layer and provides the smooth optical surface needed for clear vision. Meibomian gland dysfunction (MGD) — the most common cause of dry eye — disrupts this layer. (2) Aqueous layer (middle, thickest) — produced by the lacrimal gland (main gland, superior temporal orbit) and accessory lacrimal glands (Krause and Wolfring). Contains water, electrolytes, proteins (lysozyme, lactoferrin, immunoglobulins), and growth factors. Insufficient aqueous production leads to aqueous-deficient dry eye (Sjogren's syndrome, lacrimal gland disease). (3) Mucin layer (innermost) — produced by goblet cells in the conjunctiva. Transforms the hydrophobic corneal epithelial surface into a hydrophilic one that the aqueous layer can spread across. Without mucin, the aqueous layer would bead off the cornea like water off wax.

Q: What is the most common type of dry eye and what causes it?

Evaporative dry eye, caused by meibomian gland dysfunction (MGD), accounts for approximately 86% of all dry eye disease cases (Lemp et al., 2012). The meibomian glands become obstructed by thickened, waxy meibum secretions, which reduces or prevents lipid delivery to the tear film. Without adequate lipid, the aqueous layer evaporates much faster than normal, leaving a hyperosmolar, unstable tear film. MGD is associated with: rosacea (frequently missed — look for the skin condition), chronic blepharitis, contact lens wear (disrupts meibum delivery to tear film), aging, male sex, and Asian ethnicity. By contrast, aqueous-deficient dry eye (the classic Sjogren's type) accounts for approximately 14% of cases and is associated with autoimmune conditions where the lacrimal gland is destroyed by lymphocytic infiltration. The two types can coexist (mixed dry eye), and MGD must be treated even when an aqueous deficiency is also present.

Q: What is TBUT and how is it measured?

TBUT (Tear Break-Up Time) measures the stability of the tear film — specifically, how long it takes for the first dry spot to appear on the corneal surface after a blink. It is an indicator of lipid layer integrity and is reduced in both evaporative and aqueous-deficient dry eye. Procedure: instill a small amount of fluorescein (fluorescein strip briefly touched to the lower fornix, or from a sodium fluorescein drop). Have the patient blink two or three times to spread the dye evenly. Ask the patient to stop blinking. With the cobalt blue filter on the slit lamp, observe the tear film and time from the last blink to the first dark spot or black streak appearing on the fluorescein-stained tear film. Normal TBUT: >10 seconds. Borderline: 6-10 seconds. Abnormal: ≤5 seconds. Non-invasive TBUT (NITBUT) is measured with instruments like Keratograph without fluorescein — this is becoming the preferred method in many clinics.

Q: What is the standard treatment ladder for dry eye disease?

Dry eye treatment follows a stepwise, severity-based approach: Step 1 (mild): education (blink exercises, screen breaks, humidifier, warm compresses, lid hygiene), over-the-counter artificial tears (preservative-free preferred for frequent use — ≥4x/day, preserved drops ≤4x/day), omega-3 fatty acid supplementation. Step 2 (moderate): all Step 1 measures plus topical anti-inflammatory therapy — cyclosporine 0.05% (Restasis) or lifitegrast 5% (Xiidra), which target the underlying inflammatory cycle; topical corticosteroids (short-term pulse for flares); punctal plugs (silicone or collagen); prescription omega-3 (Vascepax). Step 3 (severe): oral antibiotics (doxycycline 100mg daily for MGD — reduces MMP-9 and meibum viscosity), autologous serum tears, scleral contact lenses for severe aqueous-deficient dry eye (create a fluid reservoir over the cornea). Step 4 (end-stage): moisture-retaining goggles, systemic immunosuppression for Sjogren's, amniotic membrane for corneal epithelial disease.

CPO Exam TopicCPOA Exam TopicEye Disease

Dry eye disease is one of the most common conditions in optometry, affecting an estimated 16 million Americans with diagnosed disease and many more with subclinical symptoms. It is a chronic, multifactorial condition of the ocular surface characterized by tear film instability, hyperosmolarity, and inflammation. For paraoptometrics, understanding the types of dry eye, how they are assessed, and what treatment options exist is essential for supporting the clinical evaluation and educating patients effectively.

A critical fact for the CPO and CPOA exams: evaporative dry eye from meibomian gland dysfunction (MGD) is by far the most common cause, accounting for approximately 86% of cases. This means the most important intervention is often warm compresses and lid hygiene to improve meibum flow, even before pharmaceutical treatment.

Dry Eye Types: Aqueous-Deficient vs Evaporative

Aqueous-Deficient (~14%)

Inadequate aqueous tear production from the lacrimal gland. Causes: Sjogren's syndrome (primary — lacrimal and salivary glands; secondary — with RA or lupus), non-Sjogren's lacrimal deficiency (age-related, post-radiation, neurotrophic). Schirmer test: severely reduced (<5mm/5min). Requires more aggressive treatment. Females aged 40-60 are most commonly affected (Sjogren's).

Evaporative (~86%)

Excessive evaporation of the tear film due to lipid layer deficiency. Most common cause: meibomian gland dysfunction (MGD). Also: blepharitis, contact lens wear, reduced blink rate (VDT use). TBUT: shortened. Schirmer may be normal. The most commonly missed diagnosis — always assess meibomian glands in dry eye patients.

Symptoms of Dry Eye Disease

Burning, stinging, or foreign body sensation ("sand in the eyes")
Dryness — paradoxically, patients may report excessive tearing (reflex hypersecretion)
Fluctuating or blurred vision that clears with blinking
Eye fatigue, especially during reading or computer work
Discomfort worse in the afternoon/evening and in windy, low-humidity, or high-altitude environments
Contact lens intolerance — lenses become uncomfortable after a few hours

Clinical Assessment Tests

TBUT (Tear Break-Up Time)

Fluorescein instilled, patient blinks, then holds gaze open. Time to first dark spot under cobalt blue light. Normal: >10s. Abnormal: ≤5s. Quick and widely used. Tests tear film stability.

Schirmer Test

Standardized paper strip in lower fornix x 5 minutes. Measures aqueous production. Normal: ≥10mm. Low (<5mm) suggests aqueous deficiency. With or without topical anesthetic.

Corneal/Conjunctival Staining

Fluorescein stains corneal epithelial defects (green under blue light). Lissamine green or rose bengal stains devitalized/dead conjunctival cells. Pattern and severity of staining guide treatment intensity.

Meibomian Gland Expression

Doctor applies gentle pressure to lid margins — evaluates the quality and quantity of meibum expressed. Normal: clear, liquid meibum. Abnormal: turbid, toothpaste-like, or absent expression indicates MGD.

SPEED/SANDE Questionnaires

Standardized patient-reported outcome questionnaires (SPEED: Standard Patient Evaluation of Eye Dryness; SANDE: Symptom Assessment iN Dry Eye). Used to quantify symptom severity and monitor treatment response.

Practice dry eye questions for your certification exam

Opterio covers dry eye types, assessment, and treatment with AI-powered explanations for CPO and CPOA candidates.

Frequently Asked Questions

What are the three layers of the tear film and what does each do?

The tear film has three distinct layers, each produced by different cells: (1) Lipid layer (outermost) — produced by meibomian glands in the tarsal plates of the eyelids. This oily layer retards evaporation of the aqueous layer and provides the smooth optical surface needed for clear vision. Meibomian gland dysfunction (MGD) — the most common cause of dry eye — disrupts this layer. (2) Aqueous layer (middle, thickest) — produced by the lacrimal gland (main gland, superior temporal orbit) and accessory lacrimal glands (Krause and Wolfring). Contains water, electrolytes, proteins (lysozyme, lactoferrin, immunoglobulins), and growth factors. Insufficient aqueous production leads to aqueous-deficient dry eye (Sjogren's syndrome, lacrimal gland disease). (3) Mucin layer (innermost) — produced by goblet cells in the conjunctiva. Transforms the hydrophobic corneal epithelial surface into a hydrophilic one that the aqueous layer can spread across. Without mucin, the aqueous layer would bead off the cornea like water off wax.

What is the most common type of dry eye and what causes it?

Evaporative dry eye, caused by meibomian gland dysfunction (MGD), accounts for approximately 86% of all dry eye disease cases (Lemp et al., 2012). The meibomian glands become obstructed by thickened, waxy meibum secretions, which reduces or prevents lipid delivery to the tear film. Without adequate lipid, the aqueous layer evaporates much faster than normal, leaving a hyperosmolar, unstable tear film. MGD is associated with: rosacea (frequently missed — look for the skin condition), chronic blepharitis, contact lens wear (disrupts meibum delivery to tear film), aging, male sex, and Asian ethnicity. By contrast, aqueous-deficient dry eye (the classic Sjogren's type) accounts for approximately 14% of cases and is associated with autoimmune conditions where the lacrimal gland is destroyed by lymphocytic infiltration. The two types can coexist (mixed dry eye), and MGD must be treated even when an aqueous deficiency is also present.

What is TBUT and how is it measured?

TBUT (Tear Break-Up Time) measures the stability of the tear film — specifically, how long it takes for the first dry spot to appear on the corneal surface after a blink. It is an indicator of lipid layer integrity and is reduced in both evaporative and aqueous-deficient dry eye. Procedure: instill a small amount of fluorescein (fluorescein strip briefly touched to the lower fornix, or from a sodium fluorescein drop). Have the patient blink two or three times to spread the dye evenly. Ask the patient to stop blinking. With the cobalt blue filter on the slit lamp, observe the tear film and time from the last blink to the first dark spot or black streak appearing on the fluorescein-stained tear film. Normal TBUT: >10 seconds. Borderline: 6-10 seconds. Abnormal: ≤5 seconds. Non-invasive TBUT (NITBUT) is measured with instruments like Keratograph without fluorescein — this is becoming the preferred method in many clinics.

How does the Schirmer test work and what does it measure?

The Schirmer test quantifies aqueous tear production by measuring how much moisture is absorbed onto a standardized paper strip placed in the lower fornix over a set time. Two versions: (1) Schirmer I (without anesthetic) — measures reflex and basic secretion combined. Paper strip placed in lower fornix for 5 minutes with eyes lightly closed. Normal: ≥10mm of wetting. Low (<5mm) suggests aqueous deficiency. (2) Schirmer I with anesthetic (modified) — anesthetic drops eliminate reflex tearing, leaving only basic secretion. More specific for lacrimal gland deficiency. (3) Schirmer II (with nasal stimulation) — tests maximal reflex secretion by stimulating the nasal mucosa; rarely used clinically. The Schirmer test has significant variability — environmental conditions, patient anxiety, and technique affect results. It is most useful when markedly low (<5mm) or combined with other dry eye tests. It does not directly measure the lipid layer or tear film stability.

What is the standard treatment ladder for dry eye disease?

Dry eye treatment follows a stepwise, severity-based approach: Step 1 (mild): education (blink exercises, screen breaks, humidifier, warm compresses, lid hygiene), over-the-counter artificial tears (preservative-free preferred for frequent use — ≥4x/day, preserved drops ≤4x/day), omega-3 fatty acid supplementation. Step 2 (moderate): all Step 1 measures plus topical anti-inflammatory therapy — cyclosporine 0.05% (Restasis) or lifitegrast 5% (Xiidra), which target the underlying inflammatory cycle; topical corticosteroids (short-term pulse for flares); punctal plugs (silicone or collagen); prescription omega-3 (Vascepax). Step 3 (severe): oral antibiotics (doxycycline 100mg daily for MGD — reduces MMP-9 and meibum viscosity), autologous serum tears, scleral contact lenses for severe aqueous-deficient dry eye (create a fluid reservoir over the cornea). Step 4 (end-stage): moisture-retaining goggles, systemic immunosuppression for Sjogren's, amniotic membrane for corneal epithelial disease.

Ready to Test Your Knowledge?

Practice with AI-powered questions and get instant explanations.

Start Practicing

Loading article...